Table 4.
Average proportion of patients detected with disease and study heterogeneity
| %Detected | 95%CI | Heterogeneity | |
|---|---|---|---|
| Suspect of Any Disease | |||
| CHOL | |||
| RP | 48% | (37%, 60%) | p<0.001 |
| RT | 81% | (74%, 88%) | p=0.45 |
| ACET | |||
| RP | 51% | (22%, 79%) | p<0.001 |
| RT | 71% | (30%, 98%) | p=0.012 |
| FACBC | |||
| RP | 40% | (27%, 54%) | p=0.58 |
| RT | 80% | (67%, 91%) | p=0.98 |
| FDG | |||
| RP | 19% | (1%, 52%) | p=0.001 |
| RT | 12% | (1%, 32%) | Single Pub.1 |
| PSMA | |||
| RP | 82% | (69%, 92%) | p=0.94 |
| RT | 96% | (79%, 99%) | p=0.71 |
| Suspect of Extra-prostatic Disease | |||
| CHOL | |||
| RP | 40% | (30%, 50%) | p<0.001 |
| RT | 38% | (21%, 57%) | p=0.003 |
| ACET | |||
| RP | 20% | (8%, 36%) | p=0.090 |
| RT | 33% | (18%, 50%) | p=0.62 |
| FACBC | |||
| RP | 33% | (8%, 65%) | Single Pub. |
| RT | 19% | (8%, 34%) | Single Pub. |
| FDG | |||
| RP | 18% | (1%, 47%) | p=0.002 |
| RT | 12% | (1%, 32%) | Single Pub. |
| PSMA | |||
| RP | 77% | (64%, 88%) | p=0.63 |
| RT | 66% | (17%, 99%) | p=0.10 |
| Suspect of Prostatic Only Disease | |||
| CHOL | |||
| RP | 10% | (5%, 15%) | p<0.001 |
| RT | 43% | (22%, 65%) | p<0.001 |
| ACET | |||
| RP | 18% | (0%, 56%) | p<0.001 |
| RT | 34% | (1%, 81%) | p=0.003 |
| FACBC | |||
| RP | 22% | (3%, 53%) | Single Pub. |
| RT | 61% | (45%, 76%) | Single Pub. |
| FDG | |||
| RP | 3% | (1%, 6%) | 0.39 |
| RT | 2% | (1%, 13%) | Single Pub. |
| PSMA | |||
| RP | 5% | (0%, 13%) | 0.35 |
| RT | 34% | (1%, 83%) | 0.10 |
| Suspect of Disease of Local Lesions | |||
| CHOL | |||
| RP | 15% | (8%, 24%) | p<0.001 |
| RT | 49% | (23%, 76%) | p<0.001 |
| ACET | |||
| RP | 32% | (11%, 57%) | p=0.001 |
| RT | 46% | (0%, 100%) | p<0.001 |
| FACBC | |||
| RP | 44% | (15%, 76%) | Single Pub. |
| RT | 80% | (67%, 91%) | p=0.98 |
| FDG | |||
| RP | 3% | (0%, 10%) | p=0.17 |
| RT | 2% | (1%, 13%) | Single Pub. |
| PSMA | |||
| RP | 5% | (0%, 13%) | p=0.35 |
| RT | 38% | (0%, 93%) | p=0.047 |
| Suspect of Disease of Lymph Node Lesions | |||
| CHOL | |||
| RP | 25% | (17%, 33%) | p<0.001 |
| RT | 28% | (9%, 53%) | p=0.002 |
| ACET | |||
| RP | 20% | (7%, 36%) | p=0.076 |
| RT | 30% | (16%, 47%) | p=0.38 |
| FACBC | |||
| RP | No Data2 | No Data | No Data |
| RT | No Data | No Data | No Data |
| FDG | |||
| RP | 6% | (3%, 12%) | p=0.36 |
| RT | 12% | (1%, 32%) | Single Pub. |
| PSMA | |||
| RP | 45% | (31%, 60%) | p=0.65 |
| RT | 62% | (7%, 100%) | p=0.047 |
| Suspect of Disease of Bone Lesions | |||
| CHOL | |||
| RP | 16% | (9%, 25%) | p<0.001 |
| RT | 19% | (10%, 32%) | p=0.33 |
| ACET | |||
| RP | 8% | (2%, 18%) | p=0.17 |
| RT | 12% | (3%, 25%) | p=0.95 |
| FACBC | |||
| RP | No Data | No Data | No Data |
| RT | No Data | No Data | No Data |
| FDG | |||
| RP | 12% | (0%, 40%) | 0.002 |
| RT | 6% | (0%, 23%) | Single Pub. |
| PSMA | |||
| RP | 25% | (13%, 39%) | 0.99 |
| RT | 32% | (0%, 87%) | 0.065 |
Abbreviations: CHOL=11C- or 18F-Choline; ACET=11C-Acetate; FACBC=anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid; FDG=18F-fluorodeoxyglucose; PSMA=tracers targeting prostate-specific membrane antigen.
1
Heterogeneity for the indicated category cannot be calculated due to the inclusion of only a single article.
2
No data are extracted from the included studies as the reported results do not satisfy the framework established in this study.